OMass Therapeutics Appoints Birgitte Volck as Non-Executive Director

OMass Therapeutics, a pioneering biotechnology firm focused on discovering medicines targeting validated ecosystems like membrane proteins and intracellular complexes, has announced the appointment of Dr. Birgitte Volck as a Non-Executive Director of its Board. With more than 25 years of experience in the biotech industry, particularly in rare diseases and precision medicine, Dr. Volck brings a wealth of knowledge to the board. Her extensive career includes leadership positions with industry giants like GSK, Amgen, Sobi, and Genzyme, as well as board roles in several prominent biotech companies. Dr. Volck's addition comes as OMass prepares to advance its lead program—a melanocortin-2 receptor antagonist for congenital adrenal hyperplasia and Cushings Syndrome—into clinical stages, leveraging its unique OdyssION drug discovery platform. OMass is backed by notable investors, including Syncona, Oxford Science Enterprises, and Sanofi Ventures, and has raised over $160 million to date.